3,303
Views
14
CrossRef citations to date
0
Altmetric
ORIGINAL ARTICLES: LUNG CANCER

Pre-operative plasma cell-free circulating tumor DNA and serum protein tumor markers as predictors of lung adenocarcinoma recurrence

ORCID Icon, ORCID Icon, ORCID Icon, , , ORCID Icon, ORCID Icon, ORCID Icon, ORCID Icon & ORCID Icon show all
Pages 1079-1086 | Received 19 Feb 2019, Accepted 12 Apr 2019, Published online: 24 Jun 2019

References

  • Cruz C, Afonso M, Oliveiros B, et al. Recurrence and risk factors for relapse in patients with non-small cell lung cancer treated by surgery with curative intent. Oncology. 2017;92:347–352.
  • Consonni D, Pierobon M, Gail MH, et al. Lung cancer prognosis before and after recurrence in a population-based setting. J Natl Cancer Instit. 2015;107:djv059.
  • Arriagada R, Auperin A, Burdett S, et al. Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data. Lancet (London, England). 2010;10375:1267–1277.
  • Nakamura H, Nishimura T. History, molecular features, and clinical importance of conventional serum biomarkers in lung cancer. Surg Today. 2017;47:1037–1059.
  • Isaksson S, Jonsson P, Monsef N, et al. CA 19-9 and CA 125 as potential predictors of disease recurrence in resectable lung adenocarcinoma. PloS One. 2017;12:e0186284.
  • Santarpia M, Liguori A, D’Aveni A, et al. Liquid biopsy for lung cancer early detection. J Thorac Dis. 2018;10:S882–s897.
  • Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142:321–346.
  • Brunnström H, Johansson L, Jirström K, et al. Immunohistochemistry in the differential diagnostics of primary lung cancer: an investigation within the Southern Swedish Lung Cancer Study. Am J Clin Pathol. 2013;140:37–46.
  • Travis WD BE, Burke AP, Marx A, Nicholson AG, eds. WHO Classification of tumours of the lung, pleura, thymus and heart. 4th ed. Lyon, France: IARC Press; 2015.
  • Travis WD, Brambilla E, Noguchi M, et al. International association for the study of lung cancer/American thoracic society/European respiratory society international multidisciplinary classification of lung adenocarcinoma. J Thoracic Oncol. 2011;6:244–285.
  • Sobin L GM WC, eds. International Union Against Cancer (UICC). TNM classification of malignant tumours. 7th ed. Chichester, UK: Wiley-Blackwell; 2009.
  • Lindquist KE, Karlsson A, Leveen P, et al. Clinical framework for next generation sequencing based analysis of treatment predictive mutations and multiplexed gene fusion detection in non-small cell lung cancer. Oncotarget. 2017;238:34796–34810.
  • RC Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. Available from: https://www.R-project.org/2018.
  • Bettegowda C, Sausen M, Leary RJ, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med. 2014;6:224ra24.
  • Abbosh C, Birkbak NJ, Wilson GA, et al. Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution. Nature. 2017;545:446–451.
  • Chen K, Zhang J, Guan T, et al. Comparison of plasma to tissue DNA mutations in surgical patients with non-small cell lung cancer. J Thoracic Cardiovasc Surg. 2017;154:1123–1131.e2.
  • Zhao H, Chen KZ, Hui BG, et al. Role of circulating tumor DNA in the management of early-stage lung cancer. Thorac Cancer. 2018;9:509–515.